No difference in eGFR slope with sparsentan versus irbesartan among patients with focal segmental glomerulosclerosis<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 8, 2023 (HealthDay News) — No significant differences are seen in the estimated glomerular filtration rate (eGFR) with sparsentan versus irbesartan among patients with focal segmental glomerulosclerosis (FSGS), according to a study published online Nov. 3 in the New England Journal of Medicine <\/em>to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held from Nov. 2 to 5 in Philadelphia.<\/p>\n Michelle N. Rheault, M.D., from the University of Minnesota Medical School in Minneapolis, and colleagues conducted a phase 3 trial involving patients with FSGS aged 8 to 75 years who were randomly assigned to receive sparsentan or irbesartan (active control) for 108 weeks (182 and 187 patients, respectively).<\/p>\n The researchers found that at 36 weeks, 42.0 and 26.0 percent of patients in the sparsentan and irbesartan groups had partial remission of proteinuria, a response that was sustained through 108 weeks. No significant between-group differences were seen in the eGFR slope at the time of the final analysis at week 108; the difference in total slope (days 1 to 108) between the groups was 0.3 mL\/min\/1.73 m2<\/sup> of body-surface area per year; the difference in the slope between the groups from week 6 to 108 was 0.9 mL\/min\/1.73 m2<\/sup>. From baseline to week 112, the mean change in eGFR was \u00e2\u0088\u009210.4 and \u00e2\u0088\u009212.1 mL\/min\/1.73 m2<\/sup> with sparsentan and irbesartan, respectively. Similar safety profiles were seen for sparsentan and irbesartan.<\/p>\n “No significant difference in eGFR slope was observed between the sparsentan group and the irbesartan group at 108 weeks, despite a relative reduction in proteinuria with sparsentan,” the authors write.<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Travere Therapeutics, which manufactures sparsentan and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n